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Abstract
Introduction: Among critically ill patients with acute kidney injury (AKI) needing continuous renal replacement
therapy (CRRT), the effect of convective (via continuous venovenous hemofiltration [CVVH]) versus diffusive (via
continuous venovenous hemodialysis [CVVHD]) solute clearance on clinical outcomes is unclear. Our objective was
to evaluate the feasibility of comparing these two modes in a randomized trial.
Methods: This was a multicenter open-label parallel-group pilot randomized trial of CVVH versus CVVHD. Using
concealed allocation, we randomized critically ill adults with AKI and hemodynamic instability to CVVH or CVVHD,
with a prescribed small solute clearance of 35 mL/kg/hour in both arms. The primary outcome was trial feasibility,
defined by randomization of >25% of eligible patients, delivery of >75% of the prescribed CRRT dose, and follow-
up of >95% of patients to 60 days. A secondary analysis using a mixed-effects model examined the impact of
therapy on illness severity, defined by sequential organ failure assessment (SOFA) score, over the first week.
Results: We randomized 78 patients (mean age 61.5 years; 39% women; 23% with chronic kidney disease; 82% with
sepsis). Baseline SOFA scores (mean 15.9, SD 3.2) were similar between groups. We recruited 55% of eligible patients,
delivered >80% of the prescribed dose in each arm, and achieved 100% follow-up. SOFA tended to decline more over
the first week in CVVH recipients (-0.8, 95% CI -2.1, +0.5) driven by a reduction in vasopressor requirements. Mortality
(54% CVVH; 55% CVVHD) and dialysis dependence in survivors (24% CVVH; 19% CVVHD) at 60 days were similar.
Conclusions: Our results suggest that a large trial comparing CVVH to CVVHD would be feasible. There is a trend
toward improved vasopressor requirements among CVVH-treated patients over the first week of treatment.
Trial Registration: ClinicalTrials.gov: NCT00675818
Introduction
Acute kidney injury (AKI) is a common complication of
critical illness, afflicting up to two-thirds of patients
admitted to the ICU [1]. A significant minority of patients
with AKI requires renal replacement therapy (RRT), and
these individuals have high short-term mortality that
ranges from 50 to 70% [2]. In an attempt to mitigate these
poor outcomes, various components of the RRT prescrip-
tion have been rigorously examined in large well-designed
randomized controlled trials (RCTs) [3-5].
The optimal mode of clearance in patients with AKI
who require renal support is an area of considerable con-
troversy resulting in significant practice variation [6].
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Hemofiltration, whereby solutes are removed by convec-
tion, facilitates the removal of both low and higher mole-
cular weight solutes, depending on the pore size of the
membrane [7]. Hemodialysis, in which solute removal
occurs via diffusion out of the bloodstream into the dialy-
sate down a concentration gradient, removes low mole-
cular weight molecules but provides limited clearance of
higher molecular weight substances. When filter charac-
teristics are kept constant, hemofiltration, which more
faithfully mimics glomerular filtration, should result in
the clearance of larger-sized solutes as compared to
hemodialysis [7]. The removal of such solutes, which
may include toxic mediators of sepsis and inflammation,
provides the theoretical underpinnings for the superiority
of hemofiltration as a renal support mode for critically ill
patients with AKI.
We conducted a multicenter pilot RCT of hemofiltration
vs. hemodialysis in critically ill patients with AKI to deter-
mine whether a larger definitive trial based on clinically
important endpoints would be feasible. In a secondary




We conducted an unblinded RCT of continuous venove-
nous hemofiltration (CVVH) vs. continuous venovenous
hemodialysis (CVVHD) with concealed allocation (http://
Clinicaltrials.gov registration number NCT00675818). Our
reporting follows the updated CONSORT statement [8].
Setting
Participants were recruited from ICUs at six academic
hospitals: Mt. Sinai Hospital (Medical-Surgical ICU),
Sunnybrook Health Sciences Centre (Critical Care Unit
and Cardiovascular ICU) and St. Michael’s Hospital
(Medical-Surgical and Cardiovascular ICUs), all in
Toronto, Canada; Victoria Hospital (Critical Care
Trauma Centre), and University Hospital (Medical/Surgical
Intensive Care Unit and Cardiac Surgery Recovery Unit),
both in London, Canada, and University of Alberta Hospital
(General Systems Intensive Care Unit) in Edmonton,
Canada. The Research Ethics Boards of Mt. Sinai Hospital,
St. Michael’s Hospital, Sunnybrook Health Sciences Centre,
London Health Sciences Centre and the University of
Alberta approved the protocol. The Applied Health
Research Centre at St. Michael’s Hospital (Toronto,
Ontario, Canada) was the trial coordinating center.
Population
We enrolled critically ill adults (≥ 16 years of age) with
AKI, defined as a serum creatinine increase ≥ 50% from
baseline (defined as the last known pre-morbid serum
creatinine or earliest value available from the current
admission). At the time of screening, at least one of the
following indications for RRT initiation needed to be
present: (i) oliguria (defined as urine output < 100 mL
in the preceding 4 hours); (ii) metabolic acidosis (serum
bicarbonate < 15 mmol/L and pH < 7.25); (iii) refractory
hyperkalemia (serum potassium > 6 mmol/L despite medi-
cal efforts at potassium removal); (iv) serum urea > 50
mmol/L, or (v) suspected uremic organ involvement (peri-
carditis, encephalopathy, neuropathy or myopathy).
Finally, participants needed to be hemodynamically
unstable, defined as Sequential Organ Failure Assessment
(SOFA)- Cardiovascular score ≥ 1 on the day of screening
(see Additional file 1 for the modified SOFA score used in
this study). This required the patient to have mean arterial
pressure < 70 mmHg or receipt of at least one vasopressor
or inotrope [9]. Patients were excluded if any one of the
following was present: receipt of any RRT within the
previous 2 months; presence of an obstructive etiology for
AKI; receipt of a kidney transplant within the preceding
year; diagnosis of rapidly progressive glomerulonephritis,
vasculitis, or acute interstitial nephritis; a clinical indica-
tion for intermittent hemodialysis (for example, the pre-
sence of a dialyzable toxin); terminal illness with an
associated life expectancy less than 2 months; moribund
status (life expectancy < 48 hours as per judgment of phy-
sicians involved in the patient’s care); prior enrolment in
this study; enrolment in a competing ICU interventional
study; non-availability of a CRRT machine, or administra-
tion of RRT for > 36 hours prior to eligibility assessment.
Patient allocation
After eligibility was confirmed, we attempted to obtain
consent from the patient or if the patient lacked capacity
to consent, his/her substitute decision maker (SDM) was
approached. A deferred consent option was approved at
three sites, which allowed patient enrollment and rando-
mization in the event of patient incapacity and the inability
to locate an SDM. Using this mechanism, patients were
randomized, and research personnel attempted to locate
an SDM every 72 hours to affirm consent for participation.
In all cases, when participants regained capacity, they were
asked to provide consent if they were initially enrolled
using a priori SDM consent or deferred consent; no parti-
cipant withdrew consent once regaining capacity. Patients
were allocated to a study group using sealed, opaque,
sequentially numbered envelopes (prepared by the coordi-
nating center) that were opened after consent was
obtained [10]. Randomization was stratified by center in
random blocks of four, six or eight. The Research Ethics
Board at each center approved the study. An independent
data and safety monitoring board tracked the trial’s
conduct.
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Study intervention
Participants randomized to CVVH were prescribed ultra-
filtration with isovolemic replacement solution (evenly
split between pre- and post-filter) to achieve a target clear-
ance of 35 mL/kg body weight/hr. The prescribed hourly
ultrafiltration rate was increased above 35 mL/kg/hr to
compensate for the reduced efficiency of clearance related
to the pre-filter component of the replacement solution
volume administered. This adjusted CVVH dose was cal-
culated from the post-filter replacement fluid (RF), pre-fil-
ter replacement fluid and blood (blood) flow rates as
follows:
Dose = Postfilter RF rate + ((Prefilter RF rate × (Blood
flow/(Blood flow + Prefilter RF rate))).
In the CVVHD arm, the dialysate flow was set to achieve
a clearance of 35 mL/kg/hr, which included a post-filter
hemofiltration flow of 100 to 200 mL/hr. This obligate
low-volume post-filter hemofiltration is utilized at partici-
pating centers to minimize the risk of blood clotting in the
machine’s deaeration chamber. Ultrafiltration performed
for achievement of net fluid balance or to compensate for
the volume of administered anticoagulants (namely, citrate
or unfractionated heparin) was not considered in the total
dose. We used the patient’s most recent measured body
weight, as recorded in the chart or estimated by the study
coordinator if no value was documented, to calculate
prescribed RRT dose. Due to difficulties in achieving the
target RRT dose as a result of high transmembrane pres-
sures in some patients with higher body mass (particularly
those randomized to CVVH), the protocol was modified
in May 2010 (21 months after randomization of the
first patient) such that the total fluid dose was capped at
4,000 mL/hr for both treatment arms, irrespective of the
patient’s weight. After this protocol change, twenty
patients were enrolled in the trial; the 4,000 mL/hr dosing
cap was invoked in six participants (five allocated to
CVVHD and one to CVVH) who would have otherwise
needed higher flows to achieve an actual total dose of
35 mL/kg/hr.
All study therapies were delivered by the Gambro Pris-
maflex™ RRT machine using the ST100 (surface area
1.0 m2) or ST150 (surface area 1.5 m2) filter sets, which
contain a polyacrylonitrile AN69 membrane (Gambro,
Richmond Hill, ON, Canada). We permitted the use of
any commercially available dialysate and replacement solu-
tions. Decisions regarding circuit anticoagulation (heparin,
regional citrate anticoagulation, or no anticoagulation) and
volume control were at the discretion of the attending
physicians. Patients remained on study therapy until
death, withdrawal of CRRT as part of withdrawal of life
support, hemodynamic stability (SOFA-cardiovascular
score < 2 for > 24 hrs) permitting stepdown to intermit-
tent hemodialysis, or recovery of kidney function (defined
as urine output > 500 mL in the preceding 12 hrs, and
most recent serum potassium < 5.5 mmol/L and serum
bicarbonate > 18 mmol/L).
Outcomes
The primary feasibility outcome of this study was the
ability to administer > 75% of the prescribed CRRT dose
to participants in each treatment arm. Secondary feasibil-
ity outcomes included the ability to enroll > 25% of fully
eligible patients and the ability to follow > 95% of
patients to 60 days following randomization (the antici-
pated follow-up period for the future definitive principal
study). Secondary outcomes included change in SOFA
score from baseline to days 1, 2 and 7, respectively,
following randomization. Serial changes in SOFA scores
have been shown to be correlated with clinical outcomes
in critically ill patients with AKI who require RRT [11].
Data collection
Trained research coordinators collected baseline clinical
and demographic data, and information on pre-existing
medical conditions. Specific risk factors for AKI were
ascertained, including recent procedures, nephrotoxins,
and sepsis (defined using consensus guidelines [12]).
SOFA score was calculated at the time of randomization
and on each day of study therapy. The SOFA-Cardiovas-
cular score was modified to include the receipt of vaso-
pressin. Patients receiving RRT on a given day were
assigned a SOFA-Renal score of 4, regardless of urine out-
put or serum creatinine. Participants were followed until
death or a maximum of 60 days from randomization, at
which time vital status and the ongoing need for RRT
among survivors were recorded.
Statistical analyses
As this was a feasibility trial with the primary objective of
informing the design of a large-scale RCT, we planned to
enroll a convenience sample of 75 participants from six
sites. Patients who were randomized but never received
RRT are described, but these individuals were replaced to
ensure that at least 75 patients received some form of
RRT. Since the primary feasibility outcome was based on
the dose of CRRT received, patients for whom dose
could not be readily calculated (those who received no
RRT or forms of RRT other than CRRT) were excluded
from the analysis related to feasibility. However, clinical
outcomes are reported for all randomized participants.
Descriptive statistics were used to characterize partici-
pants in either arm. Continuous variables are presented
as means (SD) or medians (interquartile range, IQR) and
two-group comparisons were performed with the t-test
or Wilcoxon test, as appropriate. Two-group compari-
sons involving categorical variables were carried out with
the chi square test. Analysis of covariance, adjusted for
baseline SOFA score, was used to evaluate the change in
Wald et al. Critical Care 2012, 16:R205
http://ccforum.com/content/16/5/R205
Page 3 of 9
SOFA score on days 1 and 2. Linear mixed models
adjusted for baseline SOFA score and day of study ther-
apy were used to evaluate the impact of RRT mode on
SOFA score over the first week of therapy. For the fixed
effect of treatment (that is, CVVH vs. CVVHD) 95%
confidence intervals (CI) were obtained by profiling the
log-likelihood function. All analyses were performed
using R version 2.12.0 (R Development Core Team 2010,
Vienna, Austria).
Results
We screened 347 patients; 143 were eligible for participa-
tion and 79 individuals (55.2%) were enrolled over a
24-month time period. The inability to obtain consent
from the patient or SDM was the reason for the non-
enrollment of otherwise eligible patients. One patient was
excluded shortly after enrollment after it was decided
to pursue a non-continuous form of RRT. In total,
78 patients were randomized (39 to CVVH, and 39
to CVVHD). In one case, prior to the start of therapy it
was recognized that a patient randomized to CVVHD was
inappropriately enrolled as the indication for RRT was
toxin removal rather than AKI per se. This patient
was excluded from all further analyses. Clinical outcomes
are reported in an intention-to-treat fashion for the
remaining 77 patients (CVVH, 39; CVVHD, 38). Four
patients randomized to CVVH were excluded from the
feasibility analysis, two due to death prior to commence-
ment of study RRT, and two due to receipt of continuous
venovenous hemodiafiltration as the initial mode of ther-
apy. The indication(s) for RRT was (were) oliguria, meta-
bolic acidosis, hyperkalemia and uremia in 34, 17, 6 and 8
patients, respectively, in the CVVH arm. In the CVVHD
arm, these indications guided the inclusion of 36, 15, 4
and 3 participants, respectively. In total, 73 participants
commenced the therapy to which they were randomized
(CVVH, 35; CVVHD, 38); these individuals contributed to
the analysis relating to the feasibility of treatment delivery
(Figure 1).
Baseline characteristics (Table 1)
The mean age of participants was 61.5 (SD 14.2) years and
30/77 (39%) were women. The median time from ICU
admission to randomization was 2 (IQR 2 to 8) days.
Sepsis was present in 63/77 (82%) of participants, 73/77
(95%) were mechanically ventilated and 69/77 (90%)
received vasopressors at the time of randomization. Med-
ian 24-hr urine output was 125 (IQR 50 to 250) mL.
Approximately two-thirds of participants received some
form of RRT prior to randomization, with 23/39 in the
CVVH group (59%) for a mean of 10.6 (SD 12.0) hrs, and
30/38 in the CVVHD group (79%) for a mean of 13.3
(SD 11.7) hrs. (Table 1
Features of study treatments (Table 2)
Among the 35 participants who started CVVH, RRT was
prescribed for a median of 107 (IQR 55 to 146) hrs and
delivered for 85 (IQR 43 to 128) hrs. Overall, 84.7% (95%
Figure 1 Flow of patients through the trial. RRT, renal replacement therapy; CRRT, continuous renal replacement therapy; CVVH, continuous
venovenous hemofiltration; CVVHD, continuous venovenous hemofiltration
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CI 79.1, 90.3) of the prescribed duration was delivered.
The mean weight-standardized dose was 33.6 (SD 7.4)
mL/kg/hr while CRRT was ongoing.(Table 2
CVVHD was prescribed in 38 participants for a median
of 92 (IQR 57 to 145) hrs and delivered for 76 (IQR 44
to 148) hrs. Over the course of the trial, 87.8% (95% CI
83.3, 92.3) of the prescribed duration was delivered
to patients randomized to receive CVVHD. The mean
weight-standardized delivered RRT dose was 34.7 mL/kg/
hr (SD 4.4).
Clinical outcomes
All subjects were followed to 60 days, by which point 22/
39 (56%) and 21/38 (55%) of participants assigned to
CVVH and CVVHD, respectively, had died. Among sur-
viving patients, 4/17 (24%) and 3/17 (19%) of those initially
assigned to CVVH and CVVHD respectively, were still
dependent on RRT.
After adjustment for baseline SOFA score, we found a
non-significant decline in SOFA score among participants
treated with CVVH compared to CVVHD on the first day
(-0.4, 95% CI -1.3, 0.6) and second day (-0.4, 95% CI -1.6,
0.8) following randomization. Over the first week of ther-
apy, the adjusted change in the SOFA score among partici-
pants treated with CVVH compared to CVVHD was -0.8
(95% CI -2.1, 0.5). The observed reduction appeared to be
driven by a reduction in the cardiovascular component of
the SOFA score (Figure 2).
Protocol violations and adverse events
We identified 15 protocol violations involving 15 partici-
pants. In one individual who started therapy with CVVH,
achievement of the target dose was not feasible and RRT
was supplemented with the addition of continuous dialy-
sis; ongoing difficulties with maintaining adequate small
molecule clearance using CRRT resulted in a change to
Table 1 Baseline characteristics
CVVH (n = 39) CVVHD (n = 38)
Age, years 58.8 ± 13.7 64.3 ± 14.3
Female 14 (36%) 16 (42%)
Weight, kg 86.6 ± 31.5 89.2 ± 26.4
Days from ICU admission to randomization 2 (1, 4) 2 (1, 3)
SOFA score 16.3 ± 3.3 15.5 ± 3.0
Premorbid conditions
Hypertension 19 (49%) 26 (68%)
Diabetes mellitus 9 (23%) 9 (24%)
Chronic kidney disease 5 (13%) 13 (34%)
Acute kidney injury risk factors
Sepsis 31 (79%) 32 (84%)
Cardiopulmonary bypass in past 7 days 1 (3%) 4 (11%)
IV contrast in past 7 days 9 (23%) 6 (16%)
Physiologic parameters
Urine output, mL/24 hr 125 (60, 245) 135 (46, 251)
Minimum systolic BP during 24 hr before enrolment, mmHg 94.2 ± 16.5 86.1 ± 13.5
Minimum diastolic BP during 24 hr before enrolment, mmHg 48.9 ± 8.6 47.2 ± 9.4
Laboratory parameters
Serum creatinine, µmol/L 276 (194, 352) 246 (155, 325)
Urea, mmol/L 25.8 ± 38.1 17.6 ± 12.7
Potassium, mmol/L 4.3 ± 0.7 4.1 ± 0.6
Bicarbonate, mmol/L 20.5 ± 5.9 20.2 ± 5.3
Hemoglobin, g/L 86.1 ± 16.3 90.0 ± 15.2
Platelets, × 109/L 109.6 ± 82.6 127.2 ± 80.9
WBC, × 109/L 20.2 ± 43.3 16.9 ± 10.6
ICU interventions
Duration of RRT prior to randomization, hours 8 (0, 19) 13 (1.0, 20.5)
Mechanical ventilation 37 (95%) 36 (95%)
Vasopressors 34 (87%) 35 (92%)
Total parenteral nutrition 1 (3%) 2 (5%)
Continuous data are displayed as mean ± SD or medians (interquartile range), as appropriate. Categorical variables are displayed as n (%). CRRT, continuous renal
replacement therapy; CVVH, continuous venovenous hemofiltration; CVVHD, continuous venovenous hemodialysis; BP, blood pressure; RRT, renal replacement
therapy; SOFA, Sequential Organ Failure Assessment; WBC, White blood cell.
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sustained low efficiency dialysis. In five cases (one patient
on CVVH, and four on CVVHD), stepdown from CRRT
to IHD occurred before the participant met the study-
defined criteria for hemodynamic stability. In five cases
(two patients on CVVH, and three on CVVHD), RRT was
discontinued altogether in participants who did not meet
study criteria for renal recovery.
No adverse events were attributed to the study interven-
tion in either treatment arm.
Discussion
We completed a multi-center, concealed-allocation, ran-
domized trial comparing hemofiltration and hemodialysis
in critically ill patients with AKI. This pilot trial achieved






Duration RRT prescribed, hrs 146 ± 240 145 ± 156 0.88
Duration RRT received, hrs 130 ± 222 128 ± 142 0.87
Mean pre-filter replacement solution flow, mL/hr 1533 ± 442 0 n/a
Mean post-filter replacement solution flow, mL/hr 1440 ± 488 180 ± 140 n/a
Mean dialysate flow, mL/hr 0 2871 ± 872 n/a
Mean RRT dose, mL/kg/hr 33.6 ± 7.4 34.7 ± 4.4 0.50
Prescribed dose delivered, % 84.7 ± 16.3 87.8 ± 13.7 0.73
Net ultrafiltration, L/day 1.7 ± 2.2 0.8 ± 4.1 0.98
Days on study therapy 5 (3-7) 4.50 (3.00-10.25) 0.79
Primary reason for CRRT withdrawal 0.75
Death while on CRRT 12 (35%) 10 (27%)
Kidney function recovery 7 (21%) 7 (19%)
Transfer to intermittent hemodialysis 12 (35%) 14 (38%)
Withdrawal of life support 3 (9%) 6 (16%)
Catheter changes/day of therapy 0.09 ± 0.2 0.1 ± 0.2 0.92
Units RBCs transfused/day of therapy 0.3 ± 0.3 0.4 ± 0.7 0.38
Unscheduled circuit changes/day of therapy 0.2 ± 0.3 0.2 ± 0.2 0.36
Study days with receipt of norepinephrine, % 61.8 ± 36.2 65.7 ± 7.5 0.41
Study days with receipt of vasopressin, % 35.4 ± 35.9 43.0 ± 43.6 0.51
Continuous data are displayed as mean ± standard deviation or median (interquartile range), as appropriate. Categorical variables are displayed as n (%); n/a, not
applicable. Data are restricted to patients who initiated therapy with the CRRT mode to which they had been allocated. RRT, renal replacement therapy; CRRT,
continuous renal replacement therapy; RBCs, red blood cells; CVVH, continuous venovenous hemofiltration; CVVHD, continuous venovenous hemofiltration.
Figure 2 Total and Cardiovascular (CV) Sequential Organ Failure Assessment (SOFA) scores over the first seven days following
randomization. Total SOFA scores are denoted with squares; the cardiovascular component of the SOFA score is denoted with triangles.CVVH,
continuous venovenous hemofiltration; CVVHD, continuous venovenous hemofiltration
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its primary objective of confirming the feasibility of per-
forming a large-scale trial evaluating RRT clearance
mode in AKI. There was also a non-significant trend
towards reduced organ dysfunction, driven by decreased
vasopressor requirements, early after the initiation of
RRT in patients who received hemofiltration. These feasi-
bility data and the importance of the clinical question
justify the conduct of a large trial with adequate power to
evaluate the primary outcome of 60-day mortality. With
a power of 0.80, type I error of 0.05, and a mortality
reduction of 10% in patients treated with CVVH (esti-
mated 60-day mortality in the CVVHD arm 55%), we
estimate that such a trial would require the enrolment of
nearly 400 patients per arm. A more conservative mortal-
ity reduction of 7.5% would require the enrolment of
700 patients per arm.
Little is known about the optimal mode of clearance in
renal replacement for AKI. Although both convection and
diffusion remove small molecules with equal efficiency,
convection may remove larger molecules that are not
cleared by diffusive mechanisms [13]; previous studies
have examined effects on inflammatory markers and have
been too small to reliably determine effects on clinical out-
comes. In addition, the profile of larger molecules
removed by convection is relatively non-specific and may
also include molecules that dampen inflammation or cru-
cial medications such as antibiotics [14]. A randomized
crossover study of 13 patients with AKI and the systemic
inflammatory response syndrome found that CVVH for
24 hrs reduced plasma concentrations of TNFa and
cleared more IL-6, compared to CVVHD. However, there
was no effect on plasma concentrations of IL-6, IL-10, SL-
selectin, or endotoxin [15]. Morgera and coworkers rando-
mized 24 patients with sepsis-associated AKI to treatment
with CVVH or CVVHD using a high cutoff membrane
permeable to molecules up to 60 kilodaltons in size.
Plasma concentration and clearance for IL-6 did not differ,
but clearance of IL-1 receptor antagonist, an anti-inflam-
matory mediator, was enhanced by CVVH [16]. Of note,
protein losses were higher in patients who received
CVVH. In a prospective crossover study involving 15
patients with AKI who sequentially received CVVH and
CVVHD, b2-microglobulin clearance was non-significantly
higher among CVVH recipients (P = 0.055) [17]. Among
trials focusing on clinical outcomes, a single-centre RCT
(n = 20) did not demonstrate a difference in survival, renal
recovery or ICU stay in patients treated with CVVH vs.
CVVHD administered at fixed doses of 1.7 to 2.0 L/hr
[18]. Similarly, a recent unpublished 65-patient RCT of
CVVH vs continuous venovenous hemodiafiltration (both
at 40 mL/kg/hr) did not demonstrate a survival difference
at 28 days [19].
While interventional trials involving devices and pro-
cesses of care that are susceptible to large variations in
practice are challenging, we achieved our feasibility objec-
tives. Specifically, we were able to recruit the majority of
eligible subjects, implement the protocolized therapy for
> 85% of the prescribed time and ascertain vital status at
60 days for all participants. When accounting for actual
time on therapy, the delivered dose exceeded 80% of that
prescribed in both treatment arms, thereby surpassing our
feasibility threshold of 75%. Accordingly, we believe our
study strongly supports the feasibility of a large definitive
randomized trial comparing hemofiltration and hemodia-
lysis in critically ill patients with severe AKI.
This is the largest published trial to date to study the
mode of solute clearance in AKI. Given the challenges of
recruiting participants and implementing interventions in
a population with a high burden of illness, the success of
our pilot was a necessary precursor to a principal trial
that examines patient-relevant clinical outcomes. Our
eligibility criteria were pragmatic and assured the inclu-
sion of individuals in North America who typically
receive CRRT. A minority of individuals for whom no
SDM could be found were enroled with deferred consent,
thereby limiting exclusion of potentially eligible patients
and mitigating selection bias. Of interest, no subject
enroled by deferred consent had an SDM who subse-
quently withdrew consent or withdrew consent person-
ally after regaining capacity. Finally, other than the
clearance mode, all other aspects of RRT including step-
down to intermittent hemodialysis and withdrawal of
RRT were performed in a manner consistent with usual
practice.
Our study has several limitations. As this was an
unblinded trial, we cannot exclude the effect of co-inter-
ventions in either treatment arm. However, the nature of
our intervention made blinding impractical, and we
ensured that the two groups received equivalent RRT
doses. There is also no definite intervention related to
RRT prescription that has been shown to modify out-
comes in critically ill patients with AKI. In addition, we
cannot exclude the possibility that patients who were eligi-
ble but not randomized were systematically different than
trial participants. Our protocol specified a target clearance
of 35 mL/kg/hr, which was generally achieved in both
arms. The decision to use this dose was guided by the fact
that our trial was designed when higher dose CRRT was
felt to be potentially beneficial based on data from two
trials [20,21]. This pre-dated more recent trials and meta-
analyses demonstrating no advantage of higher dose
CRRT over doses of 20 to 25 mL/kg/hr, which would
likely be the standard in a future trial comparing convec-
tion and diffusion [4,5,22,23]. However, since high dose
therapy appears safe and may positively modify the effect
of convective clearance [20], our higher dose target was
reasonable. It should be noted that while 35 ml/kg/hr was
prescribed to all participants, actual solute clearance may
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have been significantly lower due to changes in filter per-
meability [24,25]. On the other hand, when calculating the
prescribed dose, we did not consider clearance associated
with net ultrafiltration or removal of volume associated
with the administration of anticoagulants. This approach
would tend to underestimate the actual solute clearance
that was delivered. Importantly, any deviation in dose
from our 35 mL/kg/hr target would affect participants in
both intervention arms to a similar extent. The Prismaflex
CRRT system requires that all patients (even those predo-
minantly getting hemodialysis) receive a small amount of
post-filter hemofiltration (up to 200 ml/hr) to prevent
clotting in the machine’s deaeration chamber. In addition,
CVVHD recipients would have had other unavoidable
sources of convective clearance, specifically for the
achievement of net fluid removal, and for the isovolemic
removal of volume associated with the administration of
the anticoagulant (citrate or heparin). Thus, CVVHD reci-
pients did not receive purely diffusive solute clearance. We
nonetheless estimate that the typical patient enrolled in
the CVVHD arm still received > 80% of therapy in the
form of diffusive clearance, which reassures us that this
trial truly compared two different modes of solute clear-
ance. Our trial was conducted using the AN69 polyacryo-
nitrile filter, which has unique adsorptive characteristics
[14]. While this is a widely used membrane in the admin-
istration of CRRT, the adsorptive characteristics of filters
may differ and we cannot generalize our findings to set-
tings in which other filters are utilized. Moreover, we did
not collect data to evaluate the relative effect of CVVH or
CVVHD on the removal of molecules of varying size. This
trial was conducted using continuous RRT. Although the
question of hemodialysis vs. hemofiltration is applicable to
patients stable enough to receive intermittent RRT,
machines to deliver intermittent hemofiltration were not
widely available in North America when the trial was con-
ducted. Among trial participants who became more hemo-
dynamically stable, intermittent hemodialysis was utilized
even when the initial CRRT mode was hemofiltration,
thereby potentially diluting the benefits associated with
CVVH. Finally, while we observed a trend towards
improved organ failure scores, this finding must be inter-
preted with caution given the small sample size of our
trial. Moreover, disease severity scores such as the SOFA
score are surrogate markers that cannot supplant hard
clinical endpoints.
Conclusions
Our findings clearly support the feasibility of performing a
definitive trial comparing CVVH and CVVHD in critically
ill patients with AKI. The early non-significant trend
towards reduced vasopressor requirements provides preli-
minary support to the concept that convective modes of
clearance reduce inflammation and thus benefit critically
ill patients. Given the high mortality associated with AKI,
the lack of specific RRT interventions shown to reduce
mortality, and current practice variation, the results of our
pilot trial provide justification for a larger trial of hemofil-
tration vs. hemodialysis that will be adequately powered to
evaluate meaningful clinical outcomes.
Key messages
• A randomized controlled trial of hemofiltration vs
hemodialysis is feasible.
• Hemofiltration may be associated with decreased
vasopressor requirements over the first week of
therapy.
• A well-designed and adequately powered trial of
hemofiltration vs hemodialysis would address an
important area of uncertainty in the management of
patients with AKI.
Additional material
Additional file 1: Modified Sequential Organ Failure Assessment
(SOFA) score. SOFA score modified from the original version (see
reference [9]) for application in the OMAKI trial.
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